Ubs Group Ag Fsd Pharma Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.96 - $1.63 $883 - $1,499	-920 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.45 - $1.84 $600 - $761	414 Added 81.82%	920 $1,000
Q2 2021 Aug 13, 2021	SELL	$1.56 - $2.13 $976 - $1,333	-626 Reduced 55.3%	506 $1,000
Q1 2021 May 12, 2021	BUY	$1.65 - $3.87 $1,867 - $4,380	1,132 New	1,132 $2,000
Q4 2020 Feb 11, 2021	SELL	$1.36 - $2.7 $6,600 - $13,103	-4,853 Closed	0 $0

Q3 2020 Nov 12, 2020	BUY	$2.55 - $4.26 $4,653 - $7,774	1,825 Added 60.27%	4,853 $12,000
Q2 2020 Jul 31, 2020	BUY	$2.58 - $7.39 $7,812 - $22,376	3,028 New	3,028 $12,000

Ticker HUGE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 38,218,100
Market Cap $5.73M
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.